Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Doroshow Website

James H. Doroshow, M.D.

Selected Publications

1)  Esworthy RS, Kim BW, Chow J, Shen B, Doroshow JH, Chu FF.
Nox1 causes ileocolitis in mice deficient in glutathione peroxidase-1 and -2.
Free Radic. Biol. Med. 68: 315-25, 2014.
2)  Jeong W, Rapisarda A, Park SR, Kinders RJ, Chen A, Melillo G, Turkbey B, Steinberg SM, Choyke P, Doroshow JH, Kummar S.
Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1a), in patients with refractory solid tumors.
Cancer Chemother. Pharmacol. 73: 343-8, 2014.
3)  Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, Pommier YG.
Rationale for PARP inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
J. Pharmacol. Exp. Ther. [Epub ahead of print], 2014.
4)  Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, Morris J, Teicher B, Doroshow JH, Pommier Y.
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Mol. Cancer Ther. 13: 433-43, 2014.
5)  Jeong W, Park SR, Rapisarda A, Fer N, Kinders RJ, Chen A, Melillo G, Turkbey B, Steinberg SM, Choyke P, Doroshow JH, Kummar S.
Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.
Invest New Drugs. 32: 340-6, 2014.
6)  Abrams J, Mooney M, Zweibel J, Christian M, Doroshow J.
Structures Supporting Cancer Clinical Trials. In: Abeloff's Clinical Oncology. Volume 1.
Philadelphia: Elsevier; 2013. In Press. [Book Chapter]
7)  Kummar S, Murgo A, Tomaszewski J, Doroshow J.
Therapeutic Targeting of Cancer Cells: Era of Molecularly Targeted Agents. In: Abeloff's Clinical Oncology. Volume 1.
Philadelphia: Elsevier; 2013. In Press. [Book Chapter]
8)  Weil M, Kummar S, Doroshow J, Chen A.
Yang S, eds.
BRCA Mtations and PARP Inhibitors. In: Handbook of Therapeutic Biomarkers in Cancer.
Singapore: Pan Sanford Publishing Co.; 2013. p. 417-448 [Book Chapter]
9)  Park SR, Speranza G, Piekarz R, Wright JJ, Kinders RJ, Wang L, Pfister T, Trepel JB, Lee MJ, Alarcon S, Steinberg SM, Collins J, Doroshow JH, Kummar S.
A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas.
Cancer Chemother. Pharmacol. 71: 981-90, 2013.
10)  Wu Y, Lu J, Antony S, Juhasz A, Liu H, Jiang G, Meitzler JL, Hollingshead M, Haines DC, Butcher D, Roy K, Doroshow JH.
Activation of TLR4 is required for the synergistic induction of dual oxidase 2 and dual oxidase A2 by IFN-gamma and lipopolysaccharide in human pancreatic cancer cell lines.
J. Immunol. 190: 1859-72, 2013.
11)  Dodd LE, Korn EL, Freidlin B, Gu W, Abrams JS, Bushnell WD, Canetta R, Doroshow JH, Gray RJ, Sridhara R.
An audit strategy for time-to-event outcomes measured with error: Application to five randomized controlled trials in oncology.
Clin Trials. 10: 754-60, 2013.
12)  Doroshow JH, Sleijfer S, Stupp R, Anderson K.
Cancer clinical trials--do we need a new algorithm in the age of stratified medicine?.
Oncologist. 18: 651-2, 2013.
13)  Kummar S, Allen D, Monks A, Polley EC, Hose CD, Ivy SP, Turkbey IB, Lawrence S, Kinders RJ, Choyke P, Simon R, Steinberg SM, Doroshow JH, Helman L.
Cediranib for metastatic alveolar soft part sarcoma.
J. Clin. Oncol. 31: 2296-302, 2013.
14)  Antony S, Wu Y, Hewitt SM, Anver MR, Butcher D, Jiang G, Meitzler JL, Liu H, Juhasz A, Lu J, Roy KK, Doroshow JH.
Characterization of NADPH oxidase 5 expression in human tumors and tumor cell lines with a novel mouse monoclonal antibody.
Free Radic. Biol. Med. 65: 497-508, 2013.
15)  McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, Mesirov JP, Polley MY, Kim KY, Tricoli JV, Taylor JM, Shuman DJ, Simon RM, Doroshow JH, Conley BA.
Criteria for the use of omics-based predictors in clinical trials.
Nature. 502: 317-20, 2013.
16)  McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, Mesirov JP, Polley MY, Kim KY, Tricoli JV, Taylor JM, Shuman DJ, Simon RM, Doroshow JH, Conley BA.
Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration.
BMC Med. 11: 220, 2013.
17)  Doroshow JH, Gaur S, Markel S, Lu J, van Balgooy J, Synold TW, Xi B, Wu X, Juhasz A.
Effects of iodonium-class flavin dehydrogenase inhibitors on growth, reactive oxygen production, cell cycle progression, NADPH oxidase 1 levels, and gene expression in human colon cancer cells and xenografts.
Free Radic. Biol. Med. 57: 162-75, 2013.
18)  Kummar S, Anderson L, Hill K, Majerova E, Allen D, Horneffer Y, Ivy SP, Rubinstein L, Harris P, Doroshow JH, Collins JM.
First-in-Human Phase 0 Trial of Oral 5-Iodo-2-Pyrimidinone-2"-Deoxyribose in Patients with Advanced Malignancies.
Clin. Cancer Res. 19: 1852-7, 2013.
19)  Wu Y, Antony S, Hewitt SM, Jiang G, Yang SX, Meitzler JL, Juhasz A, Lu J, Liu H, Doroshow JH, Roy K.
Functional activity and tumor-specific expression of dual oxidase 2 in pancreatic cancer cells and human malignancies characterized with a novel monoclonal antibody.
Int. J. Oncol. 42: 1229-38, 2013.
20)  Abrams JS, Mooney MM, Zwiebel JA, Korn EL, Friedman SH, Finnigan SR, Schettino PR, Denicoff AM, Kruhm MG, Montello M, Misra RR, Ansher SS, DiPiazza KJ, Souhan EM, Wickerham DL, Giantonio BJ, O'Donnell RT, Sullivan DM, Soto NI, Fleming GF, Prindiville SA, Petryshyn RA, Hautala JA, Grad O, Zuckerman BL, Meyer RM, Yao JC, Baker LA, Buckner JC, Hortobagyi GN, Doroshow JH.
Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials.
J. Natl. Cancer Inst. 105: 954-9, 2013.
21)  Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, Doroshow JH, Cranston A, Martin NM, Lau A, O'Connor MJ, Ganesan S, Borst P, Jonkers J, Rottenberg S.
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
Cancer Discov. 3: 68-81, 2013.
22)  Wu Y, Antony S, Meitzler JL, Doroshow JH.
Molecular mechanisms underlying chronic inflammation-associated cancers.
Cancer Lett. 345: 164-73, 2013.
23)  Kummar S, Doroshow JH.
Molecular targets in cancer therapy.
Expert Rev Anticancer Ther. 13: 267-9, 2013.
24)  Meitzler JL, Antony S, Wu Y, Juhasz A, Liu H, Jiang G, Lu J, Roy K, Doroshow JH.
NADPH Oxidases: A Perspective on Reactive Oxygen Species Production in Tumor Biology.
Antioxid. Redox Signal. [Epub ahead of print], 2013.
25)  Doroshow JH.
Overcoming resistance to targeted anticancer drugs.
N. Engl. J. Med. 369: 1852-3, 2013.
26)  Kummar S, Gutierrez ME, Anderson LW, Klecker RW, Chen A, Murgo AJ, Doroshow JH, Collins JM.
Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.
Cancer Chemother. Pharmacol. 72: 917-23, 2013.
27)  Park SR, Davis M, Doroshow JH, Kummar S.
Safety and feasibility of targeted agent combinations in solid tumours.
Nat Rev Clin Oncol. 10: 154-68, 2013.
28)  Abaan OD, Polley EC, Davis SR, Zhu YJ, Bilke S, Walker RL, Pineda M, Gindin Y, Jiang Y, Reinhold WC, Holbeck SL, Simon RM, Doroshow JH, Pommier Y, Meltzer PS.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73: 4372-82, 2013.
29)  Steven Esworthy R, Kim B, Wang Y, Gao Q, Doroshow JH, Leto TL, Chu F.
The Gdac1 locus modifies spontaneous and Salmonella-induced colitis in mice deficient in either Gpx2 or Gpx1 gene.
Free Radic. Biol. Med. 65: 1273-1283, 2013.
30)  Doroshow JH.
Timely completion of scientifically rigorous cancer clinical trials: an unfulfilled priority.
J. Clin. Oncol. 31: 3312-4, 2013.
31)  Jeong W, Doroshow JH, Kummar S.
United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies.
Curr Probl Cancer. 37: 110-44, 2013.
32)  Do K, Doroshow JH, Kummar S.
Wee1 kinase as a target for cancer therapy.
Cell Cycle. 12: 3159-3164, 2013.
33)  Bhattacharyya S, Kurdziel K, Wei L, Riffle L, Kaur G, Hill GC, Jacobs PM, Tatum JL, Doroshow JH, Kalen JD.
Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
Nucl. Med. Biol. 40: 451-457, 2013.
34)  Kummar S, Doroshow J.
Phase 0 Trials in Oncology. In: Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Volume 1.
New York: Springer Science; 2012. In Press. [Book Chapter]
35)  Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, Gandara DR, Allen D, Kiesel B, Beumer JH, Newman EM, Rubinstein L, Chen A, Zhang Y, Wang L, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH.
A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.
Clin. Cancer Res. 18: 1726-34, 2012.
36)  Kummar S, Chen A, Parchment RE, Kinders RJ, Ji J, Tomaszewski JE, Doroshow JH.
Advances in using PARP inhibitors to treat cancer.
BMC Med. 10: 25, 2012.
37)  Esworthy RS, Kim BW, Rivas GE, Leto TL, Doroshow JH, Chu FF.
Analysis of candidate colitis genes in the Gdac1 locus of mice deficient in glutathione peroxidase-1 and -2.
PLoS ONE. 7: e44262, 2012.
38)  Do K, Doroshow JH, Kummar S.
Antiangiogenic approaches for the treatment of advanced synovial sarcomas.
Curr Opin Oncol. 24: 425-30, 2012.
39)  Doroshow JH, Juhasz A, Ge Y, Holbeck S, Lu J, Antony S, Wu Y, Jiang G, Roy K.
Antiproliferative mechanisms of action of the flavin dehydrogenase inhibitors diphenylene iodonium and di-2-thienyliodonium based on molecular profiling of the NCI-60 human tumor cell panel.
Biochem. Pharmacol. 83: 1195-207, 2012.
40)  Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, Doroshow J, Pommier Y.
CellMiner: A Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set.
Cancer Res. 72: 3499-511, 2012.
41)  Zoppoli G, Solier S, Reinhold WC, Liu H, Connelly JW, Monks A, Shoemaker RH, Abaan OD, Davis SR, Meltzer PS, Doroshow JH, Pommier Y.
CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute.
Oncogene. 31: 403-418, 2012.
42)  Schilsky RL, Doroshow JH, Leblanc M, Conley BA.
Development and use of integral assays in clinical trials.
Clin. Cancer Res. 18: 1540-6, 2012.
43)  Pfister TD, Hollingshead M, Kinders RJ, Zhang Y, Evrard YA, Ji J, Khin SA, Borgel S, Stotler H, Carter J, Divelbiss R, Kummar S, Pommier Y, Parchment RE, Tomaszewski JE, Doroshow JH.
Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues.
PLoS ONE. 7: e50494, 2012.
44)  Doroshow JH.
Dexrazoxane For The Prevention Of Cardiac Toxicity And Treatment Of Extravasation Injury From The Anthracycline Antibiotics.
Curr Pharm Biotechnol. 13: 1949-1956, 2012.
45)  Vanderwalde A, Ye W, Frankel P, Asuncion D, Leong L, Luu T, Morgan R, Twardowski P, Koczywas M, Pezner R, Paz IB, Margolin K, Wong J, Doroshow JH, Forman S, Shibata S, Somlo G.
Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer.
Biol. Blood Marrow Transplant. 18: 1273-80, 2012.
46)  Speranza G, Gutierrez ME, Kummar S, Strong JM, Parker RJ, Collins J, Yu Y, Cao L, Murgo AJ, Doroshow JH, Chen A.
Phase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumors.
Cancer Chemother. Pharmacol. 69: 431-438, 2012.
47)  Morgan RJ, Leong L, Chow W, Gandara D, Frankel P, Garcia A, Lenz H, Doroshow JH.
Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study.
Investigational new drugs. 30: 723-728, 2012.
48)  Zoppoli G, Regairaz M, Leo E, Reinhold WC, Varma S, Ballestrero A, Doroshow JH, Pommier Y.
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents.
Proc. Natl. Acad. Sci. U.S.A. 109: 15030-5, 2012.
49)  Teicher BA, Doroshow JH.
The promise of antibody-drug conjugates.
N. Engl. J. Med. 367: 1847-8, 2012.
50)  Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y.
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
Cancer Res. 72: 5588-99, 2012.
51)  Doroshow J.
Topoisomerase II Inhibitors: Anthracyclenes. In: Cancer Chemotherapy and Biotherapy: Principles and Practice. Volume 1.
Philadelphia: Lippincott, Williams, and Wilkins; 2011. p. 356-391 [Book Chapter]
52)  Martin MM, Ryan M, Kim R, Zakas AL, Fu H, Lin CM, Reinhold WC, Davis SR, Bilke S, Liu H, Doroshow JH, Reimers MA, Valenzuela MS, Pommier Y, Meltzer PS, Aladjem MI.
Genome-wide depletion of replication initiation events in highly transcribed regions.
Genome research. 21: 1822-1832, 2011.
53)  Ji J, Kinders RJ, Zhang Y, Rubinstein L, Kummar S, Parchment RE, Tomaszewski JE, Doroshow JH.
Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells.
PLoS ONE. 6: e26152, 2011.
54)  Kummar S, Raffeld M, Juwara L, Horneffer YR, Strassberger A, Allen D, Steinberg SM, Rapisarda A, Spencer SD, Figg WD, Chen X, Turkbey B, Choyke PL, Murgo AJ, Doroshow JH, Melillo G.
Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1{alpha} (HIF-1{alpha}) in Advanced Solid Tumors.
Clin. Cancer Res. 17: 5123-31, 2011.
55)  W Humphrey R, M Brockway-Lunardi L, T Bonk D, Dohoney KM, Doroshow JH, Meech SJ, Ratain MJ, Topalian SL, M Pardoll D.
Opportunities and challenges in the development of experimental drug combinations for cancer.
J. Natl. Cancer Inst. 103: 1222-6, 2011.
56)  Kummar S, Doroshow JH.
Phase 0 trials: expediting the development of chemoprevention agents.
Cancer Prev Res (Phila). 4: 288-92, 2011.
57)  Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, Jia L, Weil M, Speranza G, Murgo AJ, Kinders R, Wang L, Parchment RE, Carter J, Stotler H, Rubinstein L, Hollingshead M, Melillo G, Pommier Y, Bonner W, Tomaszewski JE, Doroshow JH.
Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas.
Cancer Res. 71: 5626-34, 2011.
58)  Kummar S, Gutierrez ME, Maurer BJ, Reynolds CP, Kang M, Singh H, Crandon S, Murgo AJ, Doroshow JH.
Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas.
Anticancer Res. 31: 961-6, 2011.
59)  Kummar S, Gutierrez ME, Chen A, Turkbey IB, Allen D, Horneffer YR, Juwara L, Cao L, Yu Y, Kim YS, Trepel J, Chen H, Choyke P, Melillo G, Murgo AJ, Collins J, Doroshow JH.
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.
Eur. J. Cancer. 47: 997-1005, 2011.
60)  Somlo G, Lashkari A, Bellamy W, Zimmerman TM, Tuscano JM, O'Donnell MR, Mohrbacher AF, Forman SJ, Frankel P, Chen HX, Doroshow JH, Gandara DR.
Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial.
British journal of haematology. 154: 533-535, 2011.
61)  Zhang YW, Regairaz M, Seiler JA, Agama KK, Doroshow JH, Pommier Y.
Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells.
Nucleic Acids Res. 39: 3607-20, 2011.
62)  Nguyen D, Zajac-Kaye M, Rubinstein L, Voeller D, Tomaszewski JE, Kummar S, Chen AP, Pommier Y, Doroshow JH, Yang SX.
Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
Cell Cycle. 10: 4074-82, 2011.
63)  Wu Y, Antony S, Juhasz A, Lu J, Ge Y, Jiang G, Roy K, Doroshow JH.
Up-regulation and sustained activation of Stat1 are essential for interferon-gamma (IFN-gamma)-induced dual oxidase 2 (Duox2) and dual oxidase A2 (DuoxA2) expression in human pancreatic cancer cell lines.
J. Biol. Chem. 286: 12245-56, 2011.
64)  Kummar S, Gutierrez ME, Gardner ER, Figg WD, Melillo G, Dancey J, Sausville EA, Conley BA, Murgo AJ, Doroshow JH.
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.
Cancer Chemother. Pharmacol. 65: 383-9, 2010.
65)  Khleif SN, Doroshow JH, Hait WN.
AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development.
Clin. Cancer Res. 16: 3299-318, 2010.
66)  Speranza G, Doroshow JH, Kummar S.
Adenocarcinoma of the small bowel: changes in the landscape?.
Curr Opin Oncol. 22: 387-93, 2010.
67)  Holbeck SL, Collins JM, Doroshow JH.
Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines.
Mol. Cancer Ther. 9: 1451-60, 2010.
68)  Freedman AN, Sansbury LB, Figg WD, Potosky AL, Weiss Smith SR, Khoury MJ, Nelson SA, Weinshilboum RM, Ratain MJ, McLeod HL, Epstein RS, Ginsburg GS, Schilsky RL, Liu G, Flockhart DA, Ulrich CM, Davis RL, Lesko LJ, Zineh I, Randhawa G, Ambrosone CB, Relling MV, Rothman N, Xie H, Spitz MR, Ballard-Barbash R, Doroshow JH, Minasian LM.
Cancer Pharmacogenomics and Pharmacoepidemiology: Setting a Research Agenda to Accelerate Translation.
J. Natl. Cancer Inst. 102: 1698-1705, 2010.
69)  Kinders R, Hollingshead MG, Lawrence S, Ji J, Tabb B, Bonner WM, Pommier Y, Rubinstein L, Evrard YA, Parchment RE, Tomaszewski JE, Doroshow JH.
Development of a Validated Immunofluorescence Assay for {gamma}H2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity.
Clin. Cancer Res. 16: 5447-57, 2010.
70)  Reinhold WC, Mergny JL, Liu H, Ryan M, Pfister TD, Kinders R, Parchment R, Doroshow J, Weinstein JN, Pommier Y.
Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron.
Cancer Res. 70: 2191-203, 2010.
71)  Redon CE, Nakamura AJ, Zhang YW, Ji JJ, Bonner WM, Kinders RJ, Parchment RE, Doroshow JH, Pommier Y.
Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers.
Clin. Cancer Res. 16: 4532-42, 2010.
72)  Wang LH, Pfister TD, Parchment RE, Kummar S, Rubinstein L, Evrard YA, Gutierrez ME, Murgo AJ, Tomaszewski JE, Doroshow JH, Kinders RJ.
Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells.
Clin. Cancer Res. 16: 1073-84, 2010.
73)  Kummar S, Gutierrez ME, Gardner ER, Chen X, Figg WD, Zajac-Kaye M, Chen M, Steinberg SM, Muir CA, Yancey MA, Horneffer YR, Juwara L, Melillo G, Ivy SP, Merino M, Neckers L, Steeg PS, Conley BA, Giaccone G, Doroshow JH, Murgo AJ.
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.
Eur. J. Cancer. 46: 340-7, 2010.
74)  Luu T, Chow W, Lim D, Koczywas M, Frankel P, Cristea M, Margolin K, Doroshow JH, Somlo G, Gaur S, Yen Y, Morgan RJ.
Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors.
Anticancer Res. 30: 167-74, 2010.
75)  Dilts DM, Cheng SK, Crites JS, Sandler AB, Doroshow JH.
Phase III clinical trial development: a process of chutes and ladders.
Clin. Cancer Res. 16: 5381-9, 2010.
76)  Morgan RJ, Synold T, Mamelak A, Lim D, Al-Kadhimi Z, Twardowski P, Leong L, Chow W, Margolin K, Shibata S, Somlo G, Yen Y, Frankel P, Doroshow JH.
Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors.
Cancer Chemother. Pharmacol. 66: 927-33, 2010.
77)  Doroshow JH.
Selecting Systemic Cancer Therapy One Patient at a Time: Is There a Role for Molecular Profiling of Individual Patients With Advanced Solid Tumors?.
J. Clin. Oncol. 28: 4869-71, 2010.
78)  Doroshow JH.
The national cancer institute experimental therapeutics program.
Clin Adv Hematol Oncol. 8: 403-4, 2010.
79)  Rubinstein LV, Steinberg SM, Kummar S, Kinders R, Parchment RE, Murgo AJ, Tomaszewski JE, Doroshow JH.
The statistics of phase 0 trials.
Stat Med. 29: 1072-6, 2010.
80)  Kummar S, Chen HX, Wright J, Holbeck S, Millin MD, Tomaszewski J, Zweibel J, Collins J, Doroshow JH.
Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements.
Nat Rev Drug Discov. 9: 843-56, 2010.
81)  Juhasz A, Ge Y, Markel S, Chiu A, Matsumoto L, van Balgooy J, Roy K, Doroshow JH.
Expression of NADPH oxidase homologues and accessory genes in human cancer cell lines, tumours and adjacent normal tissues.
Free Radic. Res. 43: 523-32, 2009.
82)  Doroshow JH, Croyle RT, Niederhuber JE.
Five strategies for accelerating the war on cancer in an era of budget deficits.
Oncologist. 14: 110-6, 2009.
83)  Yang SX, Kummar S, Steinberg SM, Murgo AJ, Gutierrez M, Rubinstein L, Nguyen D, Kaur G, Chen AP, Giranda VL, Tomaszewski JE, Doroshow JH.
Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas.
Cancer Biol. Ther. 8: 2004-9, 2009.
84)  Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A, Murgo AJ, Collins J, Steinberg SM, Eliopoulos H, Giranda VL, Gordon G, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH.
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.
J. Clin. Oncol. 27: 2705-11, 2009.
85)  Kummar S, Doroshow JH, Tomaszewski JE, Calvert AH, Lobbezoo M, Giaccone G.
Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies.
Eur. J. Cancer. 45: 741-6, 2009.
86)  Shibata SI, Doroshow JH, Frankel P, Synold TW, Yen Y, Gandara DR, Lenz H, Chow WA, Leong LA, Lim D, Margolin KA, Morgan RJ, Somlo G, Newman EM.
Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.
Cancer Chemother. Pharmacol. 64: 1149-55, 2009.
87)  Chew HK, Doroshow JH, Frankel P, Margolin KA, Somlo G, Lenz HJ, Gordon M, Zhang W, Yang D, Russell C, Spicer D, Synold T, Bayer R, Hantel A, Stiff PJ, Tetef ML, Gandara DR, Albain KS.
Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.
J. Clin. Oncol. 27: 2163-9, 2009.
88)  Doroshow JH, Kummar S.
Role of Phase 0 trials in drug development.
Future Med Chem. 1: 1375-80, 2009.
89)  Pfister TD, Reinhold WC, Agama K, Gupta S, Khin SA, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH, Pommier Y.
Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity.
Mol. Cancer Ther. 8: 1878-84, 2009.
90)  Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, Frankel P, Smith DD, Doroshow JH, Wong C, Aparicio A, Gandara DR, Somlo G.
A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study.
Clin. Cancer Res. 14: 7138-42, 2008.
91)  Doroshow JH.
Commentary: publishing cancer clinical trial results: a scientific and ethical imperative.
Oncologist. 13: 930-2, 2008.
92)  Beumer JH, Parise RA, Newman EM, Doroshow JH, Synold TW, Lenz HJ, Egorin MJ.
Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).
Cancer Chemother. Pharmacol. 62: 363-8, 2008.
93)  Murgo AJ, Kummar S, Rubinstein L, Gutierrez M, Collins J, Kinders R, Parchment RE, Ji J, Steinberg SM, Yang SX, Hollingshead M, Chen A, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH.
Designing phase 0 cancer clinical trials.
Clin. Cancer Res. 14: 3675-82, 2008.
94)  Somlo G, Chu P, Frankel P, Ye W, Groshen S, Doroshow JH, Danenberg K, Danenberg P.
Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome.
Ann. Oncol. 19: 1853-9, 2008.
95)  Doroshow JH, Parchment RE.
Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient.
Clin. Cancer Res. 14: 3658-63, 2008.
96)  Kummar S, Rubinstein L, Kinders R, Parchment RE, Gutierrez ME, Murgo AJ, Ji J, Mroczkowski B, Pickeral OK, Simpson M, Hollingshead M, Yang SX, Helman L, Wiltrout R, Collins J, Tomaszewski JE, Doroshow JH.
Phase 0 clinical trials: conceptions and misconceptions.
Cancer J. 14: 133-7, 2008.
97)  Ramanathan RK, Egorin MJ, Takimoto CH, Remick SC, Doroshow JH, LoRusso PA, Mulkerin DL, Grem JL, Hamilton A, Murgo AJ, Potter DM, Belani CP, Hayes MJ, Peng B, Ivy SP.
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
J. Clin. Oncol. 26: 563-9, 2008.
98)  Kinders RJ, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, Doroshow JH, Parchment RE.
Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts.
Clin. Cancer Res. 14: 6877-85, 2008.
99)  Tomaszewski J, Doroshow J.
Preclinical Development of Molecularly Targeted Agents in Oncology. In: Cancer Drug Discovery and Development: Molecular Targeting in Oncology.
Totowa, NJ: Humana Press; 2007. p. 703-718 [Book Chapter]
100)  Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, Collins J, Pickeral O, Low J, Steinberg SM, Gutierrez M, Yang S, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH.
Compressing drug development timelines in oncology using phase '0' trials.
Nat. Rev. Cancer. 7: 131-9, 2007.
101)  Synold TW, Takimoto CH, Doroshow JH, Gandara D, Mani S, Remick SC, Mulkerin DL, Hamilton A, Sharma S, Ramanathan RK, Lenz HJ, Graham M, Longmate J, Kaufman BM, Ivy P.
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study.
Clin. Cancer Res. 13: 3660-6, 2007.
102)  Takimoto CH, Graham MA, Lockwood G, Ng CM, Goetz A, Greenslade D, Remick SC, Sharma S, Mani S, Ramanathan RK, Synold TW, Doroshow JH, Hamilton A, Mulkerin DL, Ivy P, Egorin MJ, Grem JL.
Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function.
Clin. Cancer Res. 13: 4832-9, 2007.
103)  Gajewski E, Gaur S, Akman SA, Matsumoto L, van Balgooy JN, Doroshow JH.
Oxidative DNA base damage in MCF-10A breast epithelial cells at clinically achievable concentrations of doxorubicin.
Biochem. Pharmacol. 73: 1947-56, 2007.
104)  Kinders R, Parchment RE, Ji J, Kummar S, Murgo AJ, Gutierrez M, Collins J, Rubinstein L, Pickeral O, Steinberg SM, Yang S, Hollingshead M, Chen A, Helman L, Wiltrout R, Simpson M, Tomaszewski JE, Doroshow JH.
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
Mol. Interv. 7: 325-34, 2007.
105)  Morgan RJ, Synold TW, Xi B, Lim D, Shibata S, Margolin K, Schwarz RE, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Tetef M, Lin P, Paz B, Koczywas M, Wagman L, Chu D, Frankel P, Stalter S, Doroshow JH.
Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity.
Clin. Cancer Res. 13: 1232-7, 2007.
106)  Kummar S, Gutierrez M, Gardner ER, Donovan E, Hwang K, Chung EJ, Lee M, Maynard K, Kalnitskiy M, Chen A, Melillo G, Ryan QC, Conley B, Figg WD, Trepel JB, Zwiebel J, Doroshow JH, Murgo AJ.
Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies.
Clin Cancer Res. 13: 5411-5417, 2007.
107)  Morgan RJ, Synold TW, Gandara D, Muggia F, Scudder S, Reed E, Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S, McGonigle K, Longmate J, Yen Y, Chow W, Somlo G, Carroll M, Doroshow JH.
Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial.
Int. J. Gynecol. Cancer. 17: 373-8, 2007.
108)  Doroshow J.
Anthracyclines and Anthracenediones. In: Cancer Chemotherapy and Biotherapy: Principles and Practice.
Philadelphia: Williams and Wilkins; 2006. p. 414-450 [Book Chapter]
109)  Lara PN, Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH, Gandara DR.
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
Clin. Cancer Res. 12: 1556-63, 2006.
110)  Lara PN, Koczywas M, Quinn DI, Lenz HJ, Davies AM, Lau DH, Gumerlock PH, Longmate J, Doroshow JH, Schenkein D, Kashala O, Gandara DR.
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
J Thorac Oncol. 1: 126-34, 2006.
111)  Kummar S, Gutierrez M, Doroshow JH, Murgo AJ.
Drug development in oncology: classical cytotoxics and molecularly targeted agents.
Br J Clin Pharmacol. 62: 15-26, 2006.
112)  Acharya MR, Sparreboom A, Sausville EA, Conley BA, Doroshow JH, Venitz J, Figg WD.
Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor.
Cancer Chemother. Pharmacol. 57: 275-81, 2006.
113)  Mukhopadhyay I, Sausville EA, Doroshow JH, Roy KK.
Molecular mechanism of adaphostin-mediated G1 arrest in prostate cancer (PC-3) cells: signaling events mediated by hepatocyte growth factor receptor, c-Met, and p38 MAPK pathways.
J. Biol. Chem. 281: 37330-44, 2006.
114)  Tan AR, Moore DF, Hidalgo M, Doroshow JH, Poplin EA, Goodin S, Mauro D, Rubin EH.
Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors.
Clin. Cancer Res. 12: 6517-22, 2006.
115)  Doroshow JH, McCoy S, Macdonald JS, Issell BF, Patel T, Cobb PW, Yost KJ, Abbruzzese JL.
Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: A Southwest Oncology Group study.
Invest New Drugs. 24: 537-42, 2006.
116)  Doroshow JH.
Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity.
J. Natl. Cancer Inst. 98: 223-5, 2006.
117)  Hesketh PJ, Chansky K, Lau DH, Doroshow JH, Moinpour CM, Chapman RA, Goodwin JW, Gross HM, Crowley JJ, Gandara DR.
Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027).
J Thorac Oncol. 1: 537-44, 2006.
118)  Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, Gajewski T, Quirt I, Doroshow JH.
CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.
Cancer. 104: 1045-8, 2005.
119)  Lara PN, Law LY, Wright JJ, Frankel P, Twardowski P, Lenz HJ, Lau DH, Kawaguchi T, Gumerlock PH, Doroshow JH, Gandara DR.
Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial.
Anticancer Drugs. 16: 317-21, 2005.
120)  Margolin KA, Doroshow JH, Frankel P, Chow W, Leong LA, Lim D, McNamara M, Morgan RJ, Shibata S, Somlo G, Twardowski P, Yen Y, Kogut N, Schriber J, Alvarnas J, Stalter S.
Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.
Biol. Blood Marrow Transplant. 11: 903-11, 2005.
121)  Lim D, Morgan RJ, Akman S, Margolin K, Carr BI, Leong L, Odujinrin O, Doroshow JH.
Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy.
Invest New Drugs. 23: 235-9, 2005.
122)  Doroshow JH.
Targeting EGFR in non-small-cell lung cancer.
N. Engl. J. Med. 353: 200-2, 2005.
123)  Lara PN, Mack PC, Synold T, Frankel P, Longmate J, Gumerlock PH, Doroshow JH, Gandara DR.
The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial.
Clin. Cancer Res. 11: 4444-50, 2005.
124)  Liu G, Gandara DR, Lara PN, Raghavan D, Doroshow JH, Twardowski P, Kantoff P, Oh W, Kim K, Wilding G.
A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer.
Clin. Cancer Res. 10: 924-8, 2004.
125)  Chu FF, Esworthy RS, Chu PG, Longmate JA, Huycke MM, Wilczynski S, Doroshow JH.
Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes.
Cancer Res. 64: 962-8, 2004.
126)  Chow WA, Synold TW, Tetef ML, Longmate J, Frankel P, Lawrence J, Al-Khadimi Z, Leong L, Lim D, Margolin K, Morgan RJ, Raschko J, Shibata S, Somlo G, Twardowski P, Yen Y, Doroshow JH.
Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Cancer Chemother. Pharmacol. 54: 241-8, 2004.
127)  Lara PN, Gumerlock PH, Mack PC, Lau DH, Gandour-Edwards R, Edelman MJ, Albain KS, Law LY, Longmate J, Frankel P, Reddy GP, Israel V, Doroshow JH, Gandara DR.
Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial.
Clin Lung Cancer. 6: 102-7, 2004.
128)  Kimura T, Holland WS, Kawaguchi T, Williamson SK, Chansky K, Crowley JJ, Doroshow JH, Lenz HJ, Gandara DR, Gumerlock PH.
Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy.
Ann. N. Y. Acad. Sci. 1022: 55-60, 2004.
129)  Openshaw H, Beamon K, Synold TW, Longmate J, Slatkin NE, Doroshow JH, Forman S, Margolin K, Morgan R, Shibata S, Somlo G.
Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine.
Clin. Cancer Res. 10: 461-7, 2004.
130)  Morgan RJ, Synold TW, Gandara D, Muggia F, Scudder S, Reed E, Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S, McGonigle K, Longmate J, Yen Y, Chow W, Somlo G, Carroll M, Doroshow JH.
Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer.
Cancer Chemother. Pharmacol. 54: 283-9, 2004.
131)  Chu FF, Esworthy RS, Doroshow JH.
Role of Se-dependent glutathione peroxidases in gastrointestinal inflammation and cancer.
Free Radic. Biol. Med. 36: 1481-95, 2004.
132)  Lara PN, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Twardowski P, Doroshow JH, Gandara DR.
Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
Cancer. 100: 2125-31, 2004.
133)  Lara PN, Laptalo L, Longmate J, Lau DH, Gandour-Edwards R, Gumerlock PH, Doroshow JH, Gandara DR.
Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.
Clin Lung Cancer. 5: 231-6, 2004.
Click Here to View Collapsed Bibliography.

This page was last updated on 4/28/2014.